Starting clean and staying clean is a year-round process growers can adopt to prevent disease, control pests and prepare for ...

Diana Taurasi is a Phoenix Mercury legend, and her 2024 season was her final year. She averaged 14.9 points, 3.8 rebounds and ...

Don't toss that supermarket lemon. Learn how to grow lemon trees (Citrus x limon) from seeds to produce one of the most fragrant flowering trees around.

NANJING/NEW YORK/WALTHAM - Leads Biolabs (9887.HK) and Dianthus Therapeutics (NASDAQ:DNTH) announced today the dosing of the first subject in their Phase 1 clinical trial of LBL-047, also known as ...

Investors in Dianthus Therapeutics Inc (Symbol: DNTH) saw new options become available this week, for the August 2026 expiration. One of the key data points that goes into the price an option buyer is ...

I’ve been helping to care for my elderly parents for six years. I consider it a privilege. Yet lately I’ve felt overwhelmed—exhausted by sustained fear, grief, chaos and, yes, frustration. I know I ...

Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The company will pay as much as $1 billion to Nanjing Leads Biolabs Co. Ltd. for DNTH ...

Dianthus (DNTH) Therapeutics entered into an exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212, a first and potentially best-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor.

Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bispecific antibody designed to treat certain autoimmune disorders. Under the terms of the ...

We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Frances Solá-Santiago ...

Dianthus Therapeutics secured US$250.8m on Tuesday from its first follow-on since listing two years ago in a reverse merger. Predictably, the offering was upsized from US$150m targeted at launch. The ...

Dianthus Therapeutics (NASDAQ:DNTH) has priced its recently announced and upsized public offering, raising approximately $251 million in gross proceeds, by selling 6.49 million shares of common stock ...